Literature DB >> 16794994

Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication.

Marie-Pascale Guay1, Alice Dragomir, Danielle Pilon, Yola Moride, Sylvie Perreault.   

Abstract

UNLABELLED: The WHI was stopped prematurely because of an increased risk of breast cancer, stroke and cardiovascular diseases (CVD) in the hormone replacement therapy (HRT) arm of the trial. Changes in the use of HRT are expected.
OBJECTIVE: To assess the impact of the Women's Health Initiative (WHI) publication on the rate of HRT prescription, and the clinical characteristics and persistence rate of new users and its determinants.
METHODS: From the RAMQ databases, the total numbers of HRT prescriptions, and of new HRT's users were calculated between 2 January 1998 and 31 May 2003. To assess the clinical characteristics of women, two retrospective cohorts of new HRT's users were constructed before (pre-WHI) and after (post-WHI) the WHI study publication. The persistence rate after 1 year of follow-up was estimated using a Kaplan-Meier analysis. Cox regression models were used to estimate the rate ratio of HRT cessation.
RESULTS: The total numbers of HRT users and of new users declined respectively by 28% and 50% in post-WHI. The standard dosage of HRT was significantly less used, while the proportion of women with risk factors of CVD or at very high risk of coronary artery disease (CAD) did not change. The rate of persistence in the pre-WHI cohort was 59% compared to 45% in the post-WHI (p < 0.0001), and women with risk factors of CVD or at very high risk of CAD were less likely to cease their HRT.
CONCLUSION: One year after publication, significant changes had already occurred in the trends of use, women's characteristics and estrogen dosage. No change in the proportion of new users with CVD risk factors or at very high risk of CAD was seen. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 16794994     DOI: 10.1002/pds.1273

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  17 in total

1.  Estrogenic and progestagenic effects of extracts of Justicia pectoralis Jacq., an herbal medicine from Costa Rica used for the treatment of menopause and PMS.

Authors:  Tracie D Locklear; Yue Huang; Jonna Frasor; Brian J Doyle; Alice Perez; Jorge Gomez-Laurito; Gail B Mahady
Journal:  Maturitas       Date:  2010-05-07       Impact factor: 4.342

2.  Could recent decreases in breast cancer incidence really be due to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors in Canadian women.

Authors:  C Ineke Neutel; Howard Morrison
Journal:  Can J Public Health       Date:  2010 Sep-Oct

3.  Hormone therapy and fatal breast cancer.

Authors:  Sandra A Norman; Anita L Weber; A Russell Localio; Polly A Marchbanks; Giske Ursin; Brian L Strom; Linda K Weiss; Ronald T Burkman; Leslie Bernstein; Dennis M Deapen; Suzanne G Folger; Michael S Simon; Marion R Nadel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-05       Impact factor: 2.890

4.  Anti-obesity activity of Yamabushitake (Hericium erinaceus) powder in ovariectomized mice, and its potentially active compounds.

Authors:  Eri Hiraki; Shoko Furuta; Rika Kuwahara; Naomichi Takemoto; Toshiro Nagata; Taiki Akasaka; Bungo Shirouchi; Masao Sato; Koichiro Ohnuki; Kuniyoshi Shimizu
Journal:  J Nat Med       Date:  2017-02-08       Impact factor: 2.343

Review 5.  Printed educational materials: effects on professional practice and healthcare outcomes.

Authors:  Anik Giguère; France Légaré; Jeremy Grimshaw; Stéphane Turcotte; Michelle Fiander; Agnes Grudniewicz; Sun Makosso-Kallyth; Fredric M Wolf; Anna P Farmer; Marie-Pierre Gagnon
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

6.  Use and discontinuation of hormone replacement therapy in women with myocardial infarction: a nationwide study.

Authors:  Ditte-Marie Bretler; Peter Riis Hansen; Steen Zabell Abildstrøm; Casper Haslund Jørgensen; Rikke Sørensen; Morten Lock Hansen; Tina Ken Schramm; Ellen Løkkegaard; Christian Torp-Pedersen; Gunnar Hilmar Gislason
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

Review 7.  Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease.

Authors:  Jacqueline O'Brien; John W Jackson; Francine Grodstein; Deborah Blacker; Jennifer Weuve
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

8.  Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog).

Authors:  Whitney Wharton; Carey E Gleason; Virginia M Miller; Sanjay Asthana
Journal:  Brain Res       Date:  2013-04-17       Impact factor: 3.252

9.  Estrogenic effects of herbal medicines from Costa Rica used for the management of menopausal symptoms.

Authors:  Brian J Doyle; Jonna Frasor; Lauren E Bellows; Tracie D Locklear; Alice Perez; Jorge Gomez-Laurito; Gail B Mahady
Journal:  Menopause       Date:  2009 Jul-Aug       Impact factor: 2.953

Review 10.  Why do stress and urge incontinence co-occur much more often than expected?

Authors:  Vatche A Minassian; Walter F Stewart; Annemarie G Hirsch
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.